These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25900374)

  • 1. Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
    Wang JY; Lee CH; Yu MC; Lee MC; Lee LN; Wang JT
    Eur Respir J; 2015 Aug; 46(2):567-70. PubMed ID: 25900374
    [No Abstract]   [Full Text] [Related]  

  • 2. Fluoroquinolones in community-acquired pneumonia when tuberculosis is around: an instructive case.
    Grupper M; Potasman I
    Am J Med Sci; 2008 Feb; 335(2):141-4. PubMed ID: 18277123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How are we creating fluoroquinolone-resistant tuberculosis?
    Bernardo J; Yew WW
    Am J Respir Crit Care Med; 2009 Aug; 180(4):288-9. PubMed ID: 19661251
    [No Abstract]   [Full Text] [Related]  

  • 4. Pulmonary tuberculosis presenting as community-acquired pneumonia.
    Asnis DS; Cherian S; Sun T; Shrestha S; Santucci T
    Clin Infect Dis; 2002 Dec; 35(12):1574-5. PubMed ID: 12471584
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia.
    Yoon YS; Lee HJ; Yoon HI; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
    Int J Tuberc Lung Dis; 2005 Nov; 9(11):1215-9. PubMed ID: 16333927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.
    Grossman RF; Hsueh PR; Gillespie SH; Blasi F
    Int J Infect Dis; 2014 Jan; 18():14-21. PubMed ID: 24211230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity.
    Singh A
    Clin Infect Dis; 2007 Jul; 45(1):133; author reply 134-5. PubMed ID: 17554716
    [No Abstract]   [Full Text] [Related]  

  • 8. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis.
    Long R; Chong H; Hoeppner V; Shanmuganathan H; Kowalewska-Grochowska K; Shandro C; Manfreda J; Senthilselvan A; Elzainy A; Marrie T
    Clin Infect Dis; 2009 May; 48(10):1354-60. PubMed ID: 19348594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluoroquinolones for treatment of community-acquired pneumonia and tuberculosis: putting the risk of resistance into perspective.
    Low DE
    Clin Infect Dis; 2009 May; 48(10):1361-3. PubMed ID: 19348596
    [No Abstract]   [Full Text] [Related]  

  • 10. Pneumonia due to Pseudomonas aeruginosa: the levofloxacin clinical trials experience.
    Tennenberg AM; Davis NB; Wu SC; Kahn J
    Curr Med Res Opin; 2006 May; 22(5):843-50. PubMed ID: 16709306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Pitfall of Treatment with Tosufloxacin for Pneumonia That Might Be Lung Tuberculosis.
    Fujishima N; Komiya K; Matsunaga N; Usagawa Y; Yamasue M; Hashinaga K; Umeki K; Nureki SI; Ando M; Matsunaga T; Kadota JI
    Intern Med; 2019; 58(2):263-266. PubMed ID: 30643085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on: Does empirical treatment of community-acquired pneumonia with fluoroquinolones delay tuberculosis treatment and result in fluoroquinolone resistance in Mycobacterium tuberculosis? Controversies and solutions.
    Hara GL
    Int J Antimicrob Agents; 2012 Mar; 39(3):206-7. PubMed ID: 22305096
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.
    Dooley KE; Golub J; Goes FS; Merz WG; Sterling TR
    Clin Infect Dis; 2002 Jun; 34(12):1607-12. PubMed ID: 12032896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
    Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
    Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community acquired pneumonia.
    Lim WS
    Clin Med (Lond); 2004; 4(3):224-8. PubMed ID: 15244354
    [No Abstract]   [Full Text] [Related]  

  • 17. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR; Lemonovich TL
    Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase 2 study of the novel fluoroquinolone JNJ-Q2 in community-acquired bacterial pneumonia.
    Covington PS; Davenport JM; Andrae DA; Stryjewski ME; Turner LL; McIntyre G; Almenoff J
    J Antimicrob Chemother; 2013 Nov; 68(11):2691-3. PubMed ID: 23749951
    [No Abstract]   [Full Text] [Related]  

  • 19. The rapid development of fluoroquinolone resistance in M. tuberculosis.
    Ginsburg AS; Woolwine SC; Hooper N; Benjamin WH; Bishai WR; Dorman SE; Sterling TR
    N Engl J Med; 2003 Nov; 349(20):1977-8. PubMed ID: 14614180
    [No Abstract]   [Full Text] [Related]  

  • 20. Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms.
    Goldstein RC; Husk G; Jodlowski T; Mildvan D; Perlman DC; Ruhe JJ
    Am J Infect Control; 2014 May; 42(5):539-41. PubMed ID: 24773792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.